Ownership history in CAXTON ASSOCIATES LP · 11 quarters on record
This page tracks every 13F SEC filing in which CAXTON ASSOCIATES LP reported a position in CATALYST PHARMACEUTICALS INC (CPRX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2024 Q3 | REDUCED | 20,762 | -11,576 | -35.8% | 0.02% | $413K | $19.88 |
| 2022 Q2 | REDUCED | 32,338 | -92,264 | -74.0% | 0.02% | $227K | $7.01 |
| 2022 Q1 | ADDED | 124,602 | +83,992 | +206.8% | 0.08% | $1.0M | $8.29 |
| 2021 Q4 | UNCHANGED | 40,610 | — | 0% | 0.03% | $275K | $6.77 |
| 2021 Q3 | REDUCED | 40,610 | -2,413 | -5.6% | 0.02% | $215K | $5.30 |
| 2021 Q2 | ADDED | 43,023 | +18,431 | +74.9% | 0.03% | $247K | $5.75 |
| 2021 Q1 | UNCHANGED | 24,592 | — | 0% | 0.01% | $113K | $4.61 |
| 2020 Q4 | ADDED | 24,592 | +13,039 | +112.9% | 0.01% | $82K | $3.34 |
| 2020 Q3 | REDUCED | 11,553 | -94,149 | -89.1% | 0.00% | $34K | $2.97 |
| 2020 Q2 | ADDED | 105,702 | +79,622 | +305.3% | 0.04% | $488K | $4.62 |
As of 2025 Q4 — sorted by position size